Lasa Supergenerics share news, announcements and annual reports
NSE: LASABSE: 540702Pharmaceuticals & BiotechnologySmall Cap
Lasa Supergenerics Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Sep 2017
Last close ₹4.67down ₹0.24 (4.89%)BSE ₹5.03
Share price at the NSE close on 26 Oct 2026. Previous close ₹4.91.
26 Oct: open ₹4.86, high ₹4.86, low ₹4.67
52-week range of traded prices to 26 Oct 2026
₹4.67Low, 26 Oct 2026₹12.48High, 5 Jan 2026
- Delivery only: shares bought must be paid for in full, with no selling on the same day.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹23 Cr3,595th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 0.47
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- −24.8%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- −24.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.20
- Volume, NSEVolume. Shares traded on the last trading day. Volume in the glossary
- 42,091
Lasa Supergenerics share news and announcements
825 announcements, routine notices left out, newest first. Page 8 of 17.
Nov 2021
14 Nov · Board meeting
14 Nov · Board meeting
11 Nov · Board meeting
Meeting on 14 Nov 2021: quarterly results
Oct 2021
19 Oct · Legal
Exchange has sought clarification from Lasa Supergenerics Limited with respect to announcement dated 18-Oct-2021, regarding Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify following: 1. Expected quantum of loss/damage caused;The response of the Company is awaited.19 Oct · Legal
Clarification18 Oct · Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.
11 Oct · Shareholding for the Period Ended September 30, 2021
Shareholding Pattern for the Period Ended September 30, 2021. For more details, kindly Click ....7 Oct · Statement Of Investor Complaints For The Quarter Ended September 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 0 0 0
Sep 2021
28 Sep · Results
Details of Voting results of AGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly ....28 Sep · Meeting
Aug 2021
24 Aug · Corporate action
23 Aug · Legal
Exchange has sought clarification from Lasa Supergenerics Limited with respect to announcement dated 21-Aug-2021, regarding appointment of Mr. Shivanand hedge at its board meeting held on August 21, 2021. On basis of above the Company is required to clarify following: 1. Confirmation in compliance with SEBI Letter dated June 14, 2018 read alongwith NSE Circular dated June 20, 2018. The response of the Company is awaited.23 Aug · Legal
Clarification21 Aug · Board meeting
18 Aug · Analysts
17 Aug · Analysts
16 Aug · Results
14 Aug · Board meeting
14 Aug · Board meeting
5 Aug · Certificate Of Non-Disqualification Of Directors Under Regulation 34(3) Of SEBI(Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Financial Year Ended March 31, 2021.
Jul 2021
26 Jul · Legal
Exchange has sought clarification from Lasa Supergenerics Limited with respect to announcement dated 23-Jul-2021, regarding strikes/lockouts/disturbances. On basis of above the Company is required to clarify following: 1. Whether loss/damage covered by insurance or not including amount;2. Expected quantum of loss/damage caused;The response of the Company is awaited.26 Jul · Legal
Clarification